Impact of counterfeit drugs on the formulary decision-making process.
- Published in:
- 2004
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2004 AND VI 39 AND IP 12
Results: 18
1
2
First-time generic approvals.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 571
- Publication type:
- Article
3
Selected literature.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 591
- Publication type:
- Article
4
Select cardiovascular agents.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 591
- Publication type:
- Article
5
Obesity initiative targets associated health risks, high medical costs.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 590
- Publication type:
- Article
6
New guidance for generic drugs clarifies protocol, increases speed to market.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 590
- Publication type:
- Article
7
Rofecoxib hearings point to failures in clinical testing design, decision-making transparency.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 589
- Publication type:
- Article
8
$139 million to advance information technology, records.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 588
- Publication type:
- Article
9
Government, industry provide pharmaceutical policy outlook for 2005 and beyond.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 588
- Publication type:
- Article
10
Valdecoxib meta-analysis finds increased cardiovascular risk.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 586
- Publication type:
- Article
11
Weekly nesiritide may have greatest benefit in highest-risk heart failure patients.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 585
- Publication type:
- Article
12
Safety labeling updates &new warnings.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 586
- Publication type:
- Article
13
Worldwide study finds that fluoroquinolones are still affective against CAP.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 584
- Publication type:
- Article
14
Pipeline preview.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 568
- Publication type:
- Article
15
New molecular entities.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 568
- Publication type:
- Article
16
Impact of counterfeit drugs on the formulary decision-making process.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 577
- By:
- Publication type:
- Article
17
A year of novel pharmacologic agents in review.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 572
- Publication type:
- Article
18
FDA actions in brief.
- Published in:
- Formulary, 2004, v. 39, n. 12, p. 571
- Publication type:
- Article